The stock is showing positive momentum with a 1.26% gain in the last trading session, closing at $240.37. The RSI of 69.28 indicates the stock is approaching overbought territory but hasn't reached extreme levels yet. The stock is trading above its 20-day moving average of $230.97, suggesting a bullish short-term trend.

Recent News Impact A significant leadership change at Masimo has impacted BDX, as Katie Szyman, who currently serves as president of Becton's patient monitoring unit, is leaving to become CEO of Masimo. This transition could create some short-term uncertainty in BDX's patient monitoring division.

Technical Levels According to Fibonacci analysis:

Resistance levels: R1 at $239.84, R2 at $243.09
Support levels: S1 at $229.32, S2 at $226.07
Pivot point: $234.58

Fundamental Strength BDX maintains a strong position in the medical equipment industry, with Peter Lynch-based analysis showing a high rating of 91% based on the company's fundamentals and valuation. This suggests the stock has solid underlying business strength.

Based on the technical setup and fundamental factors, BDX appears to be a hold at current levels, with potential for modest upside if it can break above the R1 resistance level at $239.84.

What is price prediction 2025 for BDX Stock?

Based on the provided data and current market conditions, here's the price prediction for BDX stock in 2025:

BDX stock is expected to reach $295 by end of 2025, driven by strong growth in its Medical segment and the successful integration of Edwards Lifesciences' Critical Care division acquisition. The recent leadership changes at Masimo, where BDX's executive Katie Szyman was appointed as CEO, demonstrates the company's strong executive talent pool and industry influence.

The stock's technical indicators show bullish momentum with RSI at 69.28 and positive MACD at 3.10, suggesting continued upward movement from current price of $240.37.

The company's strategic focus on transitioning its portfolio toward higher-growth sectors and strong cash flow generation capabilities support this price target.

What is surpport and resistant level for BDX Stock?

The S1 support level for BDX Stock is $230.13 ,The R1 resistant level for BDX Stock is $242.44.

What is the current price of BDX Stock?

As of the end of day on 2025-01-24, the price of BDX Stock was $243.25.

What is the target price of BDX Stock?

The target price for BDX Stock according to analyst rating is 273.18, with the highest price target at 290.00 and the lowest at 245.00. Analysts have a Strong Buy rating on BDX Stock overall.

What is the market cap of Becton Dickinson and Co?

The market cap of BDX is $70.6B.

Is Becton Dickinson and Co (BDX) overvalued?

Based on the provided data, I'll analyze whether BDX is overvalued through multiple valuation metrics and recent developments.

Valuation Analysis:

BDX's current valuation metrics show concerning signs of overvaluation:

Forward P/E of 41.15 is significantly higher than historical levels
EV/EBITDA of 16.88 exceeds industry averages
P/S ratio of 3.48 indicates premium pricing
P/B ratio of 2.69 suggests moderate valuation on asset basis

Analyst Consensus:

Recent analyst actions indicate mixed sentiment. While Citigroup upgraded BDX to Strong Buy with $275 target in October 2024, the consensus price targets range from $255-$290, suggesting limited upside potential from current levels.

Recent Development Impact: A significant leadership change occurred at Masimo, with BDX's Katie Szyman departing to become Masimo's CEO, which could potentially impact BDX's patient monitoring unit's performance.

Technical Analysis:

Based on the comprehensive analysis of valuation metrics, analyst sentiment, and recent developments, BDX appears overvalued at current levels. The elevated P/E ratio, premium EV/EBITDA multiple, and limited upside potential from analyst targets support this conclusion.

What is Becton Dickinson and Co (BDX)'s business?

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

What is price prediction 2030 for BDX Stock?

Based on the provided data and market analysis, here's the price prediction for BDX stock by 2030:

Becton Dickinson (BDX) stock is projected to reach approximately $385-395 by 2030, driven by its strategic shift towards higher-growth healthcare segments and the successful integration of acquisitions like Edwards Lifesciences' Critical Care division. The company's strong cash flow generation capability and consistent dividend growth history spanning over 53 years supports this bullish outlook. The recent leadership changes in the medical technology sector and BDX's focus on advanced patient monitoring solutions indicate potential for sustained growth in the coming years [1,2].